News
CATX
0.9488
+5.41%
0.0487
Weekly Report: what happened at CATX last week (0219-0223)?
Weekly Report · 6d ago
Radiopharmaceutical market expected to reach ~$14B by 2032
The international market for radiopharmaceuticals is expected to reach $13.67B by 2032. Radiopharma market expected to grow at a compound annual growth rate of 10.2% from 2023. The rising prevalence of cancer and an aging population are among the tailwinds for market growth.
Seeking Alpha · 02/25 17:00
These Drug Companies Are Going Nuclear to Fight Cancer -- Heard on the Street
Pharmaceutical companies are spending billions to develop drugs that can target cancer like guided missiles. The field of radiopharmaceuticals is also gaining ground. The idea is to deliver chemotherapy directly to tumors. The technology could become a key part of the fight against cancer in the next decade.
The Wall Street Journal · 02/20 11:30
Weekly Report: what happened at CATX last week (0212-0216)?
Weekly Report · 02/19 09:47
12 Health Care Stocks Moving In Thursday's After-Market Session
China Pharma Holding (AMEX:CPHI) shares rose 12.7% to $0.12 during Thursday's after-market session. SenesTech (NASDAQ:SNES) shares moved upwards by 7.54%. Modular Medical stock fell 16.3% in the after-markets.
Benzinga · 02/15 21:31
Weekly Report: what happened at CATX last week (0205-0209)?
Weekly Report · 02/12 09:43
12 Health Care Stocks Moving In Friday's After-Market Session
Singular Genomics Sys (NASDAQ:OMIC) shares moved upwards by 17.9% to $0.66 during Friday's after-market session. Vaccinex stock increased by 11.61% and Celularity shares rose by 7.52%. Intelligent Bio Solutions stock declined by 15.8% during the session.
Benzinga · 02/09 21:31
12 Health Care Stocks Moving In Wednesday's Intraday Session
ThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. Femasys shares increased by 21.51% and PepGen stock rose 13.77% during the same time period. Losers include CytoMed Therapeutics and Cingulate.
Benzinga · 02/07 17:31
Perspective Therapeutics Updates Corporate Presentation Online
TipRanks · 02/06 09:59
Weekly Report: what happened at CATX last week (0129-0202)?
Weekly Report · 02/05 09:46
Expensify And 3 Other Stocks Under $3 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed higher by more than 350 points on Thursday. Expensify, Inc. And Perspective Therapeutics are two recent notable insider transactions for penny stocks.
Benzinga · 02/02 12:09
Perspective Therapeutics Signs License Agreement With Stony Brook University For Its Pre-Targeting Platform; Awarded $2.4M Small Business Innovation Research Grant From NIH
Benzinga · 02/01 13:15
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Expensify, Inc. And Rave Restaurant Group are two recent notable insider transactions for penny stocks. Perspective Therapeutics, Inc has also had a recent insider purchase of shares.
Benzinga · 01/31 11:30
Monday 1/29 Insider Buying Report: ACET, CATX
NASDAQ · 01/29 15:35
Perspective Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 60 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Recent notable insider transactions for penny stocks include Retractable Technologies, Inc. And ADM Endeavors.
Benzinga · 01/29 13:53
Weekly Report: what happened at CATX last week (0122-0126)?
Weekly Report · 01/29 09:43
Perspective gains as B. Riley sees over 100% upside on radiopharma prospects
B. Riley Securities launched its coverage of Perspective Therapeutics with a Buy rating and a 12-month target of $1.20. Analyst sees over 100% upside on radiopharma prospects for the company. Eli Lilly acquired radiopharmaceuticals company Point Biopharma in December. CATX itself announced an agreement to sell 20% of its equity to rival Lantheus.
Seeking Alpha · 01/26 19:15
B. Riley Securities Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $1.2
Benzinga · 01/26 16:39
More
Webull provides a variety of real-time CATX stock news. You can receive the latest news about Perspective Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CATX
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.